References
Higley B, Smith FW, Smith T, Gemmell HG, Das Gupta P, Gvozdanovic DV, et al. Technetium-99m-1,2-bis[bis(2-ethoxyethyl) phosphino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med 1993;34:30–8
Nakajima K, Taki J, Shuke N, Bunko H, Takata S, Hisada K. Myocardial perfusion imaging and dynamic analysis with technetium-99m tetrofosmin. J Nucl Med 1993;34:1478–84
Tamaki N, Takahashi N, Kawamoto M, Torizuka T, Tadamura E, Yonekura Y, et al. Myocardial tomography using technetium-99m-tetrofosmin to evaluate coronary artery disease. J Nucl Med 1994;35:594–600
Matsunari I, Fujino S, Taki J, Senma J, Aoyama T, Wakasugi T, et al. Quantitative rest technetium-99m tetrofosmin imaging in predicting functional recovery after revascularization: comparison with rest-redistribution thallium-201. J Am Coll Cardiol 1997;29:1226–33
Pedone C, Schinkel AF, Elhendy A, van Domburg RT, Valkema R, Biagini E, et al. Incremental prognostic value of dobutamine-atropine stress 99mTc-tetrofosmin myocardial perfusion imaging for predicting outcome in diabetic patients with limited exercise capacity. Eur J Nucl Med Mol Imaging 2005;32. DOI10.1007/s00259-005-1815-y
Wackers FJT, Berman DS, Maddahi J, Watson DD, Beller GA, Strauss HW, et al. Technetium-99m hexakis 2 methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med 1989;30:301–11
Munch G, Neverve J, Matsunari I, Schroter G, Schwaiger M. Myocardial technetium-99m-tetrofosmin and technetium-99m-sestamibi kinetics in normal subjects and patients with coronary artery disease. J Nucl Med 1997;38:428–32
Glover DK, Ruiz M, Yang JY, Smith WH, Watson DD, Beller GA. Myocardial 99mTc-tetrofosmin uptake during adenosine-induced vasodilatation with either a critical or mild coronary stenosis: comparison with 201Tl and regional myocardial blood flow. Circulation 1997;96:2332–8
Narahara KA, Villanueva-Meyer J, Thompson CJ, Brizendine M, Mena I. Comparison of thallium-201 and technetium-99m hexakis 2-methoxyisobutyl isonitrile single-photon emission computed tomography for estimating the extent of myocardial ischemia and infarction in coronary artery disease. Am J Cardiol 1990;66:1438–44
Matsunari I, Fujino S, Taki J, Senma J, Aoyama T, Wakasugi T, et al. Comparison of defect size between thallium-201 and technetium-99m tetrofosmin myocardial single-photon emission computed tomography in patients with single-vessel coronary artery disease. Am J Cardiol 1996;77:350–4
Matsunari I, Haas F, Nguyen NT, Reidel G, Wolf I, Senekowitsch-Schmidtke R, et al. Comparison of sestamibi, tetrofosmin, and q12 retention in porcine myocardium. J Nucl Med 2001;42:818–23
Flamen P, Bossuyt A, Franken PR. Technetium-99m-tetrofosmin in dipyridamole-stress myocardial SPECT imaging: intraindividual comparison with technetium-99m-sestamibi. J Nucl Med 1995;36:2009–15
Acampa W, Cuocolo A, Sullo P, Varrone A, Nicolai E, Pace L, et al. Direct comparison of technetium 99m-sestamibi and technetium 99m-tetrofosmin cardiac single photon emission computed tomography in patients with coronary artery disease. J Nucl Cardiol 1998;5:265–74
Soman P, Taillefer R, DePuey EG, Udelson JE, Lahiri A. Enhanced detection of reversible perfusion defects by Tc-99m sestamibi compared to Tc-99m tetrofosmin during vasodilator stress SPECT imaging in mild-to-moderate coronary artery disease. J Am Coll Cardiol 2001;37:458–62
Shaw LJ, Hendel R, Borges-Neto S, Lauer MS, Alazraki N, Burnette J, et al. Prognostic value of normal exercise and adenosine 99mTc-tetrofosmin SPECT imaging: results from the multicenter registry of 4,728 patients. J Nucl Med 2003;44:134–9
Borges-Neto S, Tuttle RH, Shaw LK, Smith WTt, Jain D, Coleman RE, et al. Outcome prediction in patients at high risk for coronary artery disease: comparison between 99mTc tetrofosmin and 99mTc sestamibi. Radiology 2004;232:58–65
Elhendy A, Schinkel AF, van Domburg RT, Bax JJ, Valkema R, Poldermans D. Prediction of all-cause mortality in women with known or suspected coronary artery disease by stress technetium-99m tetrofosmin myocardial perfusion imaging. Am J Cardiol 2004;93:450–2
Yokoyama I, Momomura S, Ohtake T, Yonekura K, Nishikawa J, Sasaki Y, et al. Reduced myocardial flow reserve in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1997;30:1472–7
Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). Circulation 2003;108:1404–18
Calnon DA, Glover DK, Beller GA, Vanzetto G, Smith WH, Watson DD, et al. Effects of dobutamine stress on myocardial blood flow, 99mTc sestamibi uptake, and systolic wall thickening in the presence of coronary artery stenoses: implications for dobutamine stress testing. Circulation 1997;96:2353–60
Marwick T, Willemart B, D’Hondt AM, Baudhuin T, Wijns W, Detry JM, et al. Selection of the optimal nonexercise stress for the evaluation of ischemic regional myocardial dysfunction and malperfusion. Comparison of dobutamine and adenosine using echocardiography and 99mTc-MIBI single photon emission computed tomography. Circulation 1993;87:345–54
Gunalp B, Dokumaci B, Uyan C, Vardareli E, Isik E, Bayhan H, et al. Value of dobutamine technetium-99m-sestamibi SPECT and echocardiography in the detection of coronary artery disease compared with coronary angiography. J Nucl Med 1993;34:889–94
Geleijnse ML, Elhendy A, van Domburg RT, Cornel JH, Rambaldi R, Salustri A, et al. Cardiac imaging for risk stratification with dobutamine-atropine stress testing in patients with chest pain. Echocardiography, perfusion scintigraphy, or both? Circulation 1997;96:137–47
Calnon DA, McGrath PD, Doss AL, Harrell FE Jr, Watson DD, Beller GA. Prognostic value of dobutamine stress technetium-99m-sestamibi single-photon emission computed tomography myocardial perfusion imaging: stratification of a high-risk population. J Am Coll Cardiol 2001;38:1511–7
Schinkel AF, Elhendy A, van Domburg RT, Bax JJ, Roelandt JR, Poldermans D. Prognostic value of dobutamine-atropine stress 99mTc-tetrofosmin myocardial perfusion SPECT in patients with known or suspected coronary artery disease. J Nucl Med 2002;43:767–72
Tadamura E, Iida H, Matsumoto K, Mamede M, Kubo S, Toyoda H, et al. Comparison of myocardial blood flow during dobutamine-atropine infusion with that after dipyridamole administration in normal men. J Am Coll Cardiol 2001;37:130–6
Sharir T, Germano G, Kavanagh PB, Lai S, Cohen I, Lewin HC, et al. Incremental prognostic value of post-stress left ventricular ejection fraction and volume by gated myocardial perfusion single photon emission computed tomography. Circulation 1999;100:1035–42
Abidov A, Bax JJ, Hayes SW, Hachamovitch R, Cohen I, Gerlach J, et al. Transient ischemic dilation ratio of the left ventricle is a significant predictor of future cardiac events in patients with otherwise normal myocardial perfusion SPECT. J Am Coll Cardiol 2003;42:1818–25
Author information
Authors and Affiliations
Corresponding author
Additional information
This editorial commentary refers to the article http://dx.doi.org/10.1007/s00259-005-1815-y
Rights and permissions
About this article
Cite this article
Matsunari, I., Taki, J., Nakajima, K. et al. 99mTc-tetrofosmin as a prognostic agent?. Eur J Nucl Med Mol Imaging 33, 1–3 (2006). https://doi.org/10.1007/s00259-005-1881-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-005-1881-1